Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010004 | 0.71 | MEN1 (0.51) | ALDH1A1TRPC5HSD17B10HPGDMEN1 | |
| SCHEMBL19971631 | 0.71 | MEN1 (0.51) | ALDH1A1TRPC5HSD17B10HPGDMEN1 | |
| SCHEMBL796210 | 0.71 | MEN1 (0.51) | ALDH1A1TRPC5HSD17B10HPGDMEN1 | |
| SCHEMBL31704076 | 0.68 | ALDH1A1 (0.40) | ALDH1A1TRPC5EP300HSD17B10HPGD | |
| SCHEMBL8395099 | 0.68 | ALDH1A1 (0.51) | ALDH1A1HSD17B10SIGMAR1MEN1KMT2A | |
| SCHEMBL21328320 | 0.68 | SIGMAR1 (0.46) | ALDH1A1SIGMAR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL31213736 | 0.67 | MEN1 (0.46) | ALDH1A1TRPC5HSD17B10HPGDSIGMAR1 | |
| SCHEMBL30875731 | 0.67 | ELANE (0.53) | ALDH1A1TRPC5HSD17B10HPGDSIGMAR1 | |
| SCHEMBL31213800 | 0.67 | MEN1 (0.45) | ALDH1A1TRPC5MEN1KMT2APKM | |
| SCHEMBL2865162 | 0.67 | CASP3 (0.46) | ALDH1A1HPGDMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009134616-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HDGF | ALDH1A1 1614/4885TRPC5 4821/4885EP300 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.